ÂÜÀòÂÒÂ×

Michelle Southey is a seasoned computational chemist with extensive experience in drug discovery and molecular modeling. Currently serving as Drug Maker in Residence at Curie.Bio since June 2024, Michelle has held various leadership positions at Evotec from May 2018 to June 2024, including VP, Head of Molecular Architects, and VP Computational Drug Discovery. Earlier roles at Evotec and Sterix (University of Bath) involved high-level scientific collaboration and problem-solving in drug development. Michelle holds a PhD in Computational Chemistry from the University of Bristol and an MChem in Chemistry from the University of Leeds, with additional studies at Georgia Institute of Technology.